Contract drug-development organization Ricerca Biosciences LLC is offering a new service that compares drug candidates to a large reference set of pharmacologically active compounds.
The new service, called Foresight, helps predict in vivo effects from in vitro drug data and provides insight into additional compound activities, according to a statement from Concord Township, Ohio-based Ricerca.
The analysis can help researchers avoid adverse effects and determine new indications for safe or novel compounds, according to the statement.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“Foresight provides a glimpse into the future of a compound and uses data from the past to suggest ways to increase the acuity of that vision,” Ricerca CEO Ian Lennox said.
The company is offering the service for an introductory price of $3,500 per compound.
